Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer

被引：0
|
作者：
Jinno, Hiromitsu
Sato, Tomomi
Takahashi, Maiko
Hayashida, Tetsu
Hirose, Shigemichi
Kitagawa, Yuko
机构：
[1] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan
[2] Keio Univ, Sch Med, Tokyo 160, Japan
[3] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 26期
关键词：
D O I：
10.1200/jco.2013.31.26_suppl.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
收藏
页数：1
相关论文
共 50 条
  • [31] HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch
    Dubianski, R.
    Sarnowska, E.
    Leszczynski, M.
    Kubala, S.
    Olszewski, W.
    Rusetska, N.
    Jagiello-Gruszfeld, A. I.
    Konopinski, R.
    Sarnowski, T. J.
    Siedlecki, J. A.
    Nowecki, Z. I.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Hori, Ami
    Shimoda, Masafumi
    Naoi, Yasuto
    Kagara, Naofumi
    Tanei, Tomonori
    Miyake, Tomohiro
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [33] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Ami Hori
    Masafumi Shimoda
    Yasuto Naoi
    Naofumi Kagara
    Tomonori Tanei
    Tomohiro Miyake
    Kenzo Shimazu
    Seung Jin Kim
    Shinzaburo Noguchi
    Breast Cancer Research, 21
  • [34] Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
    Li, Junjie
    Shao, Zhimin
    Xu, Binghe
    Jiang, Zefei
    Cui, Shude
    Zhang, Jin
    Liao, Ning
    Jiang, Jun
    Wang, Yongsheng
    Ouyang, Quchang
    Ying, Ziwei
    MEDICINE, 2018, 97 (21)
  • [35] A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer
    Jia, Luyao
    Ling, Yuwei
    Li, Kaifu
    Zhang, Lina
    Wang, Yajun
    Kang, Hua
    CLINICAL BREAST CANCER, 2021, 21 (06) : E654 - E664
  • [36] Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
    Ligorio, Francesca
    Di Cosimo, Serena
    Verderio, Paolo
    Ciniselli, Chiara Maura
    Pizzamiglio, Sara
    Castagnoli, Lorenzo
    Dugo, Matteo
    Galbardi, Barbara
    Salgado, Roberto
    Loi, Sherene
    Michiels, Stefan
    Triulzi, Tiziana
    Tagliabue, Elda
    El-Abed, Sarra
    Izquierdo, Miguel
    de Azambuja, Evandro
    Nuciforo, Paolo
    Huober, Jens
    Moscetti, Luca
    Janni, Wolfgang
    Coccia-Portugal, Maria Antonia
    Corsetto, Paola Antonia
    Belfiore, Antonino
    Lorenzini, Daniele
    Daidone, Maria Grazia
    Vingiani, Andrea
    Gianni, Luca
    Pupa, Serenella Maria
    Bianchini, Giampaolo
    Pruneri, Giancarlo
    Vernieri, Claudio
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (12): : 1720 - 1727
  • [37] Influencing factors of the recurrence after neoadjuvant therapy in HER2-positive breast cancer.
    Murillo, Serafin Morales
    Ariadna, Gasol Cud S.
    Der-Abrain, Noemi Tuset
    Rodriguez, Alvaro
    Sanchez, Ana Velasco
    Vilardell, Felip
    Guzman, Douglas Sanchez
    Morales, Carles Canosa
    Olive, Jordi Mele
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer
    Rastogi, Priya
    Davidson, Nancy E.
    ONKOLOGIE, 2010, 33 (8-9): : 420 - 421
  • [39] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Yamshiro, Hiroyasu
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Nishimura, Reiki
    Ohtani, Shoichiro
    Sato, Nobuki
    Takahashi, Masato
    Kamio, Takako
    Yamazaki, Kosuke
    Saito, Tsuyoshi
    Kato, Makoto
    Lee, Tecchuu
    Ohno, Shinji
    Kuroi, Katsumasa
    Takano, Toshimi
    Takada, Masahiro
    Yasuno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
  • [40] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 709 - 722
12345